We aimed to investigate the relationship between inflammation and metabolic syndrome as defined by the National Cholesterol Education Program Adults Treatment Panel III (NCEP-ATP III) diagnostic criteria in peritoneal dialysis patients. Ninety-four patients treated with peritoneal dialysis were included in the study. Patients' age, sex, weight, waist circumference, arterial blood pressure, fasting blood glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, C-reactive protein, albumin, uric acid and fibrinogen levels were recorded. Fourty-one patients diagnosed with metabolic syndrome and 53 peritoneal dialysis patients without metabolic syndrome were identified. In the metabolic syndrome group mean decrease in serum albumin and mean increase in C-reactive protein and fibrinogen was significantly different from the other group (p<O.05, p<O.05, p<O.05, respectively). When gender, diabetes mellitus, and hypertension status were evaluated, the difference was not significant (p> 0.05). Peritoneal dialysis patients with metabolic syndrome should also be assessed for inflammation.
Peritoneal dialysis (PO), in end stage renal failure (ESRF) patients as renal replacement therapy, has been a successful treatment method for the past 30 years (I). PO treatment is preferred due to several reasons such as better control of blood pressure and biochemical parameters, independence of hospitalhealth services, better quality of'life, control ofanemia and lower costs in respect to hemodialysis. Various survival rates have been reported in the literature from different countries and different areas (1-4).
Metabolic syndrome (MS) is the sum of cardiovascular risk factors. Glucose intolerance or type II diabetes mellitus, hypertension, obesity, dyslipidemia and insulin resistance are the classical components of MS. It is also associated with coagulation defects, autonomic neuropathy, decrease at physical activity, cigarette use, altered sexual hormones, decreased growth hormone levels and glucocorticoid receptor dysfunctions (5) (6) (7) .
The relationship between chronic inflammation and cardiovasculer diseases in ESRF patients is well known (8) (9) (10) (11) . Also the relationship between MS and chronic inflammation has been shown (12, 13) but there has not been sufficient research to show the relationship between inflammation and ESRF patients with MS.
The aim ofthis study is to investigate the relationship between the C-reactive protein, albumin, uric acid and fibrinogen which are inflammation markers, in ESRF patients undergoing PO treatment with or without MS according to the National Cholesterol Education Program Adults Treatment Panel III (NCEP-ATP III)) diagnostic criteria.
MATERIALS AND METHODS
Ninety-four consecutive ESRF patients (51 female, 43 male) on peritoneal dialysis were included in the study. Inclusion criteria were newly diagnosed ESRF patients who had started peritoneal dialysis in our center. Patients with incomplete file data and the patients lost during the folIow-up period were excluded. Each patient's age, sex, weight, waist circumferences, arterial blood pressure, fasting blood glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, C-reactive protein, albumin, uric acid and fibrinogen levels were recorded.
Serum C-reactive protein levels were measured using latex-enhanced nephelometry (Behring Nephelometer Analyzer System: Behring Diagnostics, Somerville, NJ).
Normal cut off value of <3.0 mg/dl was used, Patients who had elevated serum CRP levels underwent laboratory (ESR, leucocytosis etc.) and physical examination in order to evaluate whether they had infections of various systems. Blood samples for CRP were obtained from infected patients after at least 21 days of treatment. Plasma fibrinogen was measured using enzyme assay methods with Coag-A-Mate XC plus (Organon-Tecnika, Alamogordo, NM). Normal cut-off value of I75-400mg/dl was used. Uric acid was measured with Hitachi 737 Analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN). Normal cut off value of7mg/dl was used.
Measurements of weight (to the nearest 0.5 kg) and height (to the nearest 0.5 ern) were carried out wearing underwear. Waist circumference measuremet was made from the narrowest point of the waist at the line between the anterior superior iliac spine and lowest rib with mild expiration while patient was standing straight.
The arterial blood pressure measurement were taken from both arms using a mercury sphingomanometer, based on Korotkoffphase I and phase 4 sounds, in a seated position after a ten-minute rest. Blood pressure values were recorded two times with at least 3 minute intervals.
NCEP -ATP III diagnostic criteria (14): three of folIowing 5 criteria were required: I) abdominal obesity (waist eircumference > 102 em in men and> 88 cm in women; 2) fasting hypertriglyceridemia (~1.7mmol/1 or 150mg/dl); 3) low fasting HDL-cholesterol « 1.04mmol or 40mg/dl in men and < 1.29mmol/1 or 50mg/dl in women); 4) high blood pressure (~130/85mlnHg or current treatment with antihypertensive medication); 5) high fasting glucose (~6.1 mmol/I, or II Omg/dl) or current treatment with antidiabetic medication.
Statistical analysis
The student's t-test was used to compare weight, waist circumference, total cholesterol, HDL-cholesterol, triglyseride, C-reactive protein, albumin, uric acid and fibrin ogene values, and X 2 test was used to compare gender, hypertension and diabetus melIitus ratios in patient with and without metabolic syndrome. SPSS 11.5 packet program was used. The p value lesser than 0.05 was accepted as significant.
RESULTS
The mean age of the PD patients (54.3% female, 45.7% male) was 58.4±13 years (ranked from 18 to 92) and the median age was 57. Demographic characteristics and etiology of chronic renal failure in groups are given in Table I . We failed to find statistically significant differences between the groups (p>O.05). Forty-one (43.6%) patients met diagnostic criterias of MS based on NCEP-ATP III criteria; and 53 (56.4%) did not.
The demographic charesteristics, serum mean fasting glucose,total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyseride, albumin, C-reactive proteine (CRP), uric acid and fibrinogen levels and statistical analysis results are given in Table II. Age. weight, mean levels of waist circumference, total cholesterol, LDL-cholesterol and trigliseride were higher in PD patients with metabolic syndrome (p<O.OO 1). HDL-cholesterol and uric acid levels were not statistically significant (p>O.05).
The inflammation markers which are decreased mean serum albumin levels. high eRP values, and increased fibrinogen levels were statistically significantly more frequent in PD patients with MS when compared to PD patients without MS (p<O.05, p<O.05, p<O.05).
In this study; 28 of41 PD patients with MS and 32 of 53 PD patients without MS had diabetus mellitus diagnosis. Also 15 of the PD patients with MS and 13 of the PD patients without MS had hypertension. When the two groups were compared for gender, diabetus mellitus and hypertension there were no statistically significant differences (p>O.05).
DISCUSSION
This study aims to investigate aSSOCIatIOn between imftammation marker levels which are C- (14) diagnostic criteria. 43.6% of the PO patients had MS and 56.4% did not. In literature, metabolic syndrome frequency in hemodialysis patients changes according to the method used and patient number. Johnson et a\. (15) found MS frequency as 50% in PO patients and 20% in hemodialysis patients based on World Health Organisation (WHO) metabolic syndrome diagnostic criteria. In our study, MS percentage based on the NCEP-ATP III diagnostic criteria in PO patients is similar to the literature findings.
C-reactive protein is a major acute phase reactant defined a long time ago. The serum concentration of CRP increases in inflammation, infection and tissue injury. CRP level can increase up to 500 or 1000 times the normal levels. This increase depends on the secretion of acute phase proteins by hepatocystes (16, 17) . Most of the studies in literature point out meaningfully high CRP levels in MS patients (18, 19) . This study points out high CRP levels in the MS group when compared to the non-MS group. Our results are similar to the literature findings. But there have not been sufficient studies on PD patients with MS.
Uric acid is an oxidation product catalysed by xanthine oxidase, and free oxygen radicals are produced during this reaction. Therefore, it has been proposed that uric acid itself ,except from renal functions, is an indicator of endothelial injury (20, 21) . Researches conducted revealed significantly high uric acid levels in metabolic syndrome patients (22, 23) . In this study there was not a significant difference in uric acid levels in PD patients with and without MS. We hypothesize that this is because of the fact that uric acid excretion is decreased in ESRF.
Serum albumin is a negative acute phase reactant, the level of which decreases in inflammation. Serum CRP and other acute phase reactants increase in inflammation whereas albumin levels decrease. Albumin synthesis decreases in inflammation; and there are worsening factors like decreased calory intake and inreasead catabolism in ESRF (24, 25) . There is no research in literature which investigates the association between albumin and MS in dialysis patients.
Fibrinogen also is an acute phase reactant as is CRP. High serum levels result in platelet aggregation, coagulation and vascular endothelial dysfunction. It has been shown that elevated fibrinogen level is an independent cardiovasculer risk factor. Weight loss, regular physical exercise, giving up tobacco usage and use of benzofibrate decreases serum levels of fibrinogen. Still there is no specific agent which selectively decreases fibrinogen levels (26, 27) . We found significantly higher fibrinogen levels in PD patients with MS compared to PD patients without MS.
In conclusion, because of high levels of CRP and fibrinogen which are cardiovascular risk factors and acute phase reactants associated with MS, and high percentage ofMS in PD patients, we suggest regular screening of these patients for MS diagnosis and evaluation of inflammation.
